Novartis has been investing heavily in its cardiovascular pipeline this year, forging partnerships with Flagship startup ...

Tourmaline Bio shares skyrocketed Tuesday after Novartis agreed to buy the cardiovascular-focused biotech company for $1.4 ...

Novartis is paying $1.4 billion to get its hands on Tourmaline Bio and its former Pfizer cardiovascular drug that impressed ...